# 2026-12620: Master Protocol Guidance Aims to Streamline Drug Trials

2026-12620, Master Protocols for Drug and Biological Product Development; Draft Guidance for Industry; Availability, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2026-06-24, effective 2026-06-24; PRIA reads it as touching household money (as of 2026-07-01).

- Canonical: https://policyrisk.com/federal-register/2026-12620
- As of: 2026-07-01
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-12620
- Title: Master Protocols for Drug and Biological Product Development; Draft Guidance for Industry; Availability
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 37991
- Published: 2026-06-24
- Effective: 2026-06-24
- Comments close: 2026-08-24
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-07-01

## In one line

Master Protocol Guidance Aims to Streamline Drug Trials

## Summary

The FDA just dropped a fresh draft guidance to help drug and biological product makers run smarter, faster clinical trials using master protocols. This update affects companies developing new medicines by clarifying how to design and submit these trials for approval. If you’re in the game, get your comments in by August 24, 2026, or risk missing out on shaping the final rules—and maybe saving time and money down the road!

## Abstract

The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Master Protocols for Drug and Biological Product Development." This draft guidance revises and replaces the previous draft guidance for industry of the same name issued on December 22, 2023. The draft guidance provides recommendations on the design and analysis of trials conducted under a master protocol as well as guidance on submissions to support regulatory review. The primary focus is on randomized trials utilizing a master protocol that are intended to contribute to a demonstration of safety and substantial evidence of effectiveness. The considerations in this guidance apply to a range of therapeutic areas. The draft guidance is intended to clarify the Agency's thinking on the use of master protocols in drug and biological product development.

## Effects PRIA read

- Clearer Rules for Master Protocol Submissions: benefit, medium. The FDA published a revised draft guidance on master protocols on June 24, 2026 that replaces the December 22, 2023 draft. The document gives recommendations on how to design randomized master-protocol trials and how to prepare submissions to support FDA regulatory review.
- Master Protocols Can Speed Development: benefit, medium. The guidance says well-designed master protocols can accelerate drug development by maximizing information from research and may offer logistical advantages like shared visit schedules, shared infrastructure, and shared oversight. It also notes some master protocols may improve efficiency by using…
- Master Protocols Add Complexity and Startup Time: cost, medium. The FDA notes master protocols also add complexity, which can increase trial start-up time and create design challenges (for example, maintaining adequate blinding). Trials involving multiple parties will require a high degree of coordination.
- More Detail on Basket Trials and Technical Topics: benefit, low. This revised draft includes more detailed recommendations regarding basket trials and discusses technical topics such as randomization, control groups, informed consent, blinding, adaptive design, multiplicity, safety, oversight, data sharing, and submissions for regulatory review. The guidance ref…
- Guidance Includes Participant Safety and Data Integrity Focus: benefit, medium. The draft guidance discusses considerations related to ensuring participant safety and data integrity in master-protocol trials and recommends principles for oversight and communication between sponsors and FDA. These considerations apply across a range of therapeutic areas.

## Related documents

- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27
- [2026-20727](https://policyrisk.com/federal-register/2026-20727): Medical Devices; Immunology and Microbiology Devices; Classification of the System for Detection of Nucleic Acid From Non-Viral Microorgani…, 2026-10-09

## Sources
- [2026-12620 on federalregister.gov](https://www.federalregister.gov/documents/2026/06/24/2026-12620/master-protocols-for-drug-and-biological-product-development-draft-guidance-for-industry)
- [2026-12620 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-06-24/pdf/2026-12620.pdf)

## Related
- [Previous: 2026-12619, Quantitative Systems Pharmacology (QSP)-Based Dose Selection for Minimum Antici…](https://policyrisk.com/federal-register/2026-12619)
- [Next: 2026-12621, Expedited Investigational New Drug Pilot Program; Request for Information](https://policyrisk.com/federal-register/2026-12621)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-12620 (as of 2026-07-01).